Humanin vs MOTS-c: What's the Difference?

Humanin and MOTS-c differ in three concrete ways: the mitochondrial gene that encodes each one, the receptor and signaling pathway each activates, and the research focus each one draws. Humanin is studied mainly in cytoprotection and neurodegeneration; MOTS-c, in energy metabolism and exercise-induced signaling. Both belong to the same family — mitochondrial-derived peptides, or MDPs — but they are not the same peptide and they do not act through the same pathway.

What are mitochondrial-derived peptides (MDPs)

Mitochondria carry their own DNA, separate from the nucleus, and for decades the assumption was that this DNA only coded for proteins in the respiratory chain. Starting in 2001, evidence began to show that certain regions of the mitochondrial genome also encode small peptides that get released outside the mitochondrion and act as signals. Humanin was the first one described, identified in a 2001 study published in PNAS using brain tissue from Alzheimer's disease patients. MOTS-c was described more than a decade later, in a 2015 paper in Cell Metabolism that linked it to metabolic regulation.

Both share an origin — they are products of genes located within mitochondrial DNA — but they are encoded in different regions and trigger mechanisms that do not overlap.

The source gene: 16S rRNA vs. 12S rRNA

The most basic difference between the two is where they come from within the mitochondrial genome:

• Humanin is encoded within an open reading frame located in the 16S ribosomal RNA gene (16S rRNA).
• MOTS-c is encoded within the 12S ribosomal RNA gene (12S rRNA).

Coming from different genes is not an incidental detail: it explains why research on each peptide developed separately, and why the two do not share an amino acid sequence or a comparable tertiary structure. There is no functional overlap that should be expected just because they share a mitochondrial origin.

Mechanism of action: receptors and pathways each one activates

The published literature describes distinct signaling mechanisms for each peptide.

Humanin binds a receptor complex that includes CNTFR (ciliary neurotrophic factor receptor) together with WSX-1 and gp130, activating the STAT3 pathway. That mechanism is what underlies the research line on its cytoprotective role: in vitro studies associate it with reduced apoptosis induced by various forms of cellular stress, which is what drove the initial interest in neurodegeneration models.

MOTS-c, by contrast, does not go through that receptor. The available evidence links it to activation of AMPK (AMP-activated protein kinase), a central cellular energy sensor, and to nuclear translocation under metabolic stress conditions, where it participates in regulating genes tied to glucose metabolism. That pathway is why a large share of MOTS-c research is concentrated in exercise and metabolic regulation models, not in neurodegeneration.

In short: the two share the prefix "mitochondrial" but they do not share a receptor, they do not share an intracellular signaling pathway, and they do not share the phenotype studied in each experimental model.

What each peptide is being researched for

With Humanin, the published literature concentrates on:

• Cytoprotection models against oxidative stress and apoptosis.
• Neurodegeneration research, particularly in the context where it was first discovered (Alzheimer's disease).
• Studies on endothelial dysfunction and in vitro cardiovascular models.

With MOTS-c, the literature concentrates on:

• Regulation of glucose metabolism and insulin sensitivity in animal models.
• Exercise response: circulating MOTS-c levels vary with physical activity in published studies, which positioned it as a research subject in exercise physiology.
• Cellular aging and energy homeostasis.

Both remain the subject of active research, and in neither case is there an approved indication for use in humans or animals. These are basic-research findings, not compounds with an established clinical application.

Documentation and purity: what to check on a MOTS-c batch

From PeptoClinic's catalog, MOTS-c is the compound with a published lab report: the MOTS-c batch was analyzed by Janoshik Analytical, and that batch showed a purity of 99.669%. That is the figure to ask for whenever a MOTS-c batch is being evaluated, regardless of the source — a label that says "99% HPLC" is not enough on its own; the number has to be backed by a certificate of analysis from an independent laboratory that can be verified. The MOTS-c Argentina page has the detail on what documentation ships with the batch.

Humanin is not part of PeptoClinic's current catalog, so there is no proprietary certificate of analysis to cite here — any purity figure a supplier shows for Humanin still needs to be checked against the laboratory report that signs it, not against what the label claims. The guide on how to read a certificate of analysis explains which fields to check before accepting any purity number, whether for MOTS-c, Humanin, or any other compound in the catalog.

Laboratory research use only

Everything described in this article corresponds to findings from in vitro and animal-model research. Neither Humanin nor MOTS-c is approved for human or veterinary use, neither is a drug or a supplement, and no regulatory authority has evaluated the claims that appear in the scientific literature cited here. Material supplied by PeptoClinic is provided strictly for research (Research Use Only, RUO): in vitro and laboratory research, not for human or animal consumption, diagnosis, or treatment.